Our top pick for
Sunshine Biopharma is conducting a public offering of units comprised of one share of common stock and one warrant exercisable for one share of common stock. The offering, however, is contingent upon the approval of the company's application for listing on the Nasdaq.
The company's stock currently trades on the Over-the-Counter Markets pink sheets under the ticker symbol "SBFM." If its application is approved, it will trade on the Nasdaq under the same ticker symbol.
|Latest market close||$0.83|
|52-week range||$0.70 - $29.80|
|50-day moving average||$1.11|
|200-day moving average||$1.93|
|Wall St. target price||N/A|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.21|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-09-20)||-3.65%|
|1 month (2022-08-26)||-26.02%|
|3 months (2022-06-28)||-29.18%|
|6 months (2022-03-28)||-66.86%|
|1 year (2021-09-28)||630.04%|
|2 years (2020-09-25)||4,503.33%|
|3 years (2019-09-27)||45,933.33%|
|5 years (2017-09-27)||5,211.54%|
|Gross profit TTM||$110,596|
|Return on assets TTM||-7.69%|
|Return on equity TTM||-25.1%|
|Market capitalisation||$15.2 million|
TTM: trailing 12 months
We're not expecting Sunshine Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Sunshine Biopharma's shares were split on a 1:200 basis on 9 February 2022. So if you had owned 200 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sunshine Biopharma shares – just the quantity. However, indirectly, the new 19900% higher share price could have impacted the market appetite for Sunshine Biopharma shares which in turn could have impacted Sunshine Biopharma's share price.
Over the last 12 months, Sunshine Biopharma's shares have ranged in value from as little as $0.701 up to $29.8. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sunshine Biopharma's is -1.6848. This would suggest that Sunshine Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Sunshine Biopharma has bucked the trend.
To put Sunshine Biopharma's beta into context you can compare it against those of similar companies.
Sunshine Biopharma, Inc. , a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.